Advanced glycation end-product levels in subtotally nephrectomized rats: Beneficial effects of angiotensin II receptor 1 antagonist losartan

Mineral and Electrolyte Metabolism

Volumn 25, Issue 4-6, 1999, Pages 380-383

  Šebeková, Katarína ^a   Schinzel, Reinhard ^c   Münch, Gerald ^c   Krivošíková, Zora ^a   Dzúrik, Rastislav ^a   Heidland, August ^b  

^a INST OF PREV AND CLINICAL MEDICINE   (Slovakia)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c NONE

Author keywords

Advanced glycation end products; Angiotensin II receptor 1 antagonist; Rat remnant kidney model

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CREATININE; LOSARTAN; TRANSFORMING GROWTH FACTOR BETA1; UREA;

ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; KIDNEY DISEASE; KIDNEY FUNCTION; NONHUMAN; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URINARY EXCRETION;

EID: 0033398586     PISSN: 03780392     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057478     Document Type: Conference Paper

References (20)

1. Bucala R, Cerami A: Advanced glycosylation: Chemistry, biology, and implications for diabetes and ageing. Adv Pharmacol 1992;23:1-34.
2. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YD, Pinsky D, Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptor binding proteins. J Biol Chem 1994;269: 9889-9897.
3. Bucalla R, Makita Z, Koschinsky T: Lipid advanced glycosylation: Pathway for lipid peroxidation in vivo. Proc Natl Acad Sci USA 1993; 90:6434-6438.
4. Bucalla R, Makita Z, Vega G: Modification of low density lipoproteins by advanced glycation end-products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994;91:9441-9445.
5. Monnier VM, Cerami A: Nonenzymatic browning in vivo: Possible process for ageing of long-lived proteins. Science 1981;211:491-493.
6. Miyata T, Shinzato T, Iida Y, Maeda K: Accumulation of albumin-linked and free form pentosidine in circulation of uremic patients with end-stage renal failure: Renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 1996;7:1198-1206.
7. ε-(carboxymethyl)lysine is increased in uremia. Kidney Int 1997;52:1064-1067.
8. Münch G, Keis R, Wessels A, Riederer P, Heidland A, Niwa T, Lemke HD, Schinzel R: Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 1997;35:669-677.
9. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, Maeda K, Kurokawa K, De Strihou CV: Implication of an increased oxidative stress in the formation of the advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997;51:1170-1181.
10. Gugliucci A, Bendayan M: Renal fate of circulating advanced glycated end products (AGE): Evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 1996;39:149-160.
11. Deppisch R, Nawroth P, Ritz E: Toxicity of uraemia. Does it come of AGE? Nephrol Dial Transplant 1994;9:1-2.
12. Lewis EJ, Hunsicker LG, Bain RP, Rhode RD: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
13. Xiang G, Schinzel R, Münch G, Simm A, Wanner C, Sebekova K, Heidland A: Losartan blocks the AGE-induced expression of TGF-β in human tubule and LLC-PK1 cells. J Am Soc Nephrol 1999;10:A3511.
14. Morrison AB: Experimentally induced chronic renal insufficiency in the rat. Lab Invest 1962; 11:321-332.
15. Williams GR, Harrison TR, Grollmann A: A simple method for determining the systolic blood pressure in unanesthetised rats. J Clin Invest 1939;18:373-383.
16. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end-products in patients with diabetic nephropathy. N Engl J Med 1991;325:836-842.
17. ras and MAP kinase via the receptor for AGEs (RAGE). Circulation 1995;92:532-540.
18. Vlassara H, Striker EJ, Teichberg S, Fuh H, Li YM, Steffes M: Advanced glycosylation end-products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994;91:11704-11707.
19. Šebcková K, Schinzel R, Ling H, Simm A, Xiang G, Gekle M, Münch G, Vamvakas S, Heidland A: Advanced glycated albumin impairs protein degradation in the kidney proximal tubules cell line LLC-PK1. Cell Mol Biol 1998;44:1051-1060.
20. Simm A, Münch G, Seif F, Schenk O, Heidland A, Richter H, Vamvakas S, Schinzel R: Advanced glycation end products stimulate the MAP-kinase pathway tubulus cell line LLC-PK1. FEBS Lett 1997;410:481-484.